Drug Type Bispecific antibody, Enzyme |
Synonyms- |
Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), Hyaluronic acid modulators, c-Met inhibitors(Hepatocyte growth factor receptor inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseNDA/BLA |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Non-Small Cell Lung Cancer | NDA/BLA | US | 17 Jun 2024 | |
EGFR-mutated non-small Cell Lung Cancer | Phase 3 | ES | 05 Aug 2022 | |
EGFR-mutated non-small Cell Lung Cancer | Phase 3 | US | 05 Aug 2022 | |
EGFR-mutated non-small Cell Lung Cancer | Phase 3 | GB | 05 Aug 2022 | |
EGFR-mutated non-small Cell Lung Cancer | Phase 3 | FR | 05 Aug 2022 | |
EGFR-mutated non-small Cell Lung Cancer | Phase 3 | IL | 05 Aug 2022 | |
EGFR-mutated non-small Cell Lung Cancer | Phase 3 | AU | 05 Aug 2022 | |
EGFR-mutated non-small Cell Lung Cancer | Phase 3 | TH | 05 Aug 2022 | |
EGFR-mutated non-small Cell Lung Cancer | Phase 3 | IT | 05 Aug 2022 | |
EGFR-mutated non-small Cell Lung Cancer | Phase 3 | JP | 05 Aug 2022 |